glp 2(rat)

intestinal epithelium-specific growth factor

GLP-2(rat) TFA, an intestinal growth factor, promotes cell proliferation and prevents apoptosis. Additionally, it increases mucosal mass and function in the residual small intestine following massive small bowel resection (MSBR), as documented in references [1] [2].

LY2922470 reduces glucose levels along with significant enhancements in insulin and GLP-1, which is the potential for the treatment of type 2 diabetes mellitus (T2DM). LY2922470 is an effective, selective, and orally available agonist of the G protein-cou

ZP3022 is a dual agonist targeting the glucagon-like peptide 1 receptor (GLP-1R) and cholecystokinin 2 (CCK2) receptor. It selectively enhances cAMP accumulation or ERK phosphorylation in HEK293 cells with GLP-1R or CCK2 receptor expression, compared to ERK phosphorylation in cells with the CCK1 receptor (EC50s: 0.02, 10.3, and >1,000 nM for human receptors, respectively). At 40 nM, ZP3022 promotes proliferation of rat neonatal β-cells in vitro. It also boosts glucose-induced insulin secretion (GSIS) in rat pancreatic islets at 10 and 100 nM concentrations and decreases body weight in rats at 40 nmol/kg doses twice daily. Administered at 100 nmol/kg daily, ZP3022 enhances β-cell and total pancreatic mass and improves glucose tolerance in db/db mice, while reducing food intake but not body weight in these mice.

SGLT2-IN-5 (Compound 99) is an orally active SGLT2 inhibitor with IC₅₀ values of 0.8 nM for SGLT2, 23 nM for SGLT1, and 58 nM for DPP4. In diabetic rat models, SGLT2-IN-5 effectively regulates blood glucose and increases the levels of active GLP-1. It is suitable for research on type 2 diabetes.

SGLT2-IN-6 (Compound 101) is an orally active SGLT2 inhibitor with IC₅₀ values of 0.8 nM, 6.7 nM, and 72 nM for SGLT2, SGLT1, and DPP4, respectively. In diabetic rat models, SGLT2-IN-6 controls blood glucose levels and increases active GLP-1 levels. It is suitable for research on type 2 diabetes.

PACAP-related peptide (PRP) is an endogenous 29-amino acid peptide that belongs to the secretin/glucagon superfamily of peptides, which includes secretin , glucagon , glucagon-like peptide-1 , GLP-2 , and pituitary adenylate cyclase-activating polypeptide . It is expressed in rat hypothalamus as well as within the nerves of the median eminence, the anterior pituitary, bed nucleus of the stria terminalis, cerebellum, cerebral cortex, and amygdala. PRP is also expressed in vaginal, uterine cervical, uterine horn, fallopian tube, and ovarian tissues from the rat female genital tract and is present in extracts of male testis tissue.

GEP44 is a peptide-biased triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), neuropeptide Y1 receptor (Y1-R), and neuropeptide Y2 receptor (Y2-R). It induces GLP-1R-dependent insulin secretion in rat and human islets by offsetting the actions of Y1-R and GLP-1R agonism, controlled by Y1-R antagonists. Additionally, GEP44 enhances glucose uptake in muscle tissue through Y1-R mediation independent of insulin and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 is utilized in studies related to obesity and type 2 diabetes.